Contraindicated (1)pentobarbital will reduce the extent or outcome of cariprazine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. CYP3A4 is liable for the development and elimination of cariprazine's Lively metabolites.
pentobarbital will lower the level or effect of meloxicam by impacting hepatic enzyme CYP2C9/ten metabolism. Minimal/Significance Mysterious.
Warning when discontinuing CYP3A4 inducers which have been coadministered with hydrocodone; plasma concentrations of hydrocodone may possibly improve and may result in probably lethal respiratory depression
pentobarbital will lessen the extent or result of pitolisant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. Pitolisant publicity is lowered by 50% if coadministered with robust CYP3A4 inducers.
Continuously check very important signs throughout sedation and recovery period if coadministered. Cautiously titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
pentobarbital will minimize the extent or impact of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the extent or outcome of cilostazol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will minimize the level or impact of ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Reserve concomitant prescribing of those drugs in clients for whom other remedy selections are insufficient. Restrict dosages and durations into the minimum necessary. more info Watch intently for indications of respiratory despair and sedation.
pentobarbital will lower the extent or influence of atazanavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.
pentobarbital will decrease the level or outcome of eucalyptus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Mysterious.
pentobarbital will lower the level or outcome of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will reduce the extent or result of voriconazole by influencing hepatic enzyme CYP2C9/ten metabolism. Insignificant/Importance Mysterious.